Welcome to our dedicated page for Optinose SEC filings (Ticker: OPTN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking drug-device innovators like Optinose can feel overwhelming. Clinical trial updates for XHANCE, FDA correspondence, and the science behind the Exhalation Delivery System are scattered across dense exhibits. When analysts ask “How do I read Optinose’s 10-K annual report?” or “Where can I find Optinose insider trading Form 4 transactions?” they just want Optinose SEC filings explained simply—not a 300-page puzzle.
Stock Titan resolves that complexity with AI-powered summaries that turn every filing into clear insights. Our platform surfaces Optinose Form 4 insider transactions real-time, pinpoints liquidity and R&D spend in each Optinose quarterly earnings report 10-Q filing, and delivers the Optinose annual report 10-K simplified in minutes. Need an alert when management posts an Optinose 8-K material events explained notice? Or a quick read-out of phase-3 data? You’ll have it. We even tag every section so understanding Optinose SEC documents with AI becomes a two-click task, not an afternoon project.
Use Stock Titan to:
- Monitor Optinose executive stock transactions Form 4 before material events
- Compare XHANCE sales trends with our Optinose earnings report filing analysis
- Review the Optinose proxy statement executive compensation without decoding lengthy tables
- Stay ahead of trial milestones through each Optinose 8-K material events explained filing
Real-time EDGAR updates, comprehensive coverage of all forms, and concise AI commentary mean investors can focus on decisions, not document hunting.
Schedule 13G/A filing by Nantahala Capital Management, LLC and two individuals reporting zero beneficial ownership in OptiNose, Inc. The filing states that as of June 30, 2025, Nantahala and its managing members, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 0 shares of OptiNose common stock (CUSIP 68404V209), representing 0.00% of the class. The filing identifies Nantahala as an investment adviser organized in Massachusetts and lists the reporting persons' business address in New Canaan, Connecticut. Signatures include Nantahala through its Chief Compliance Officer and both individual reporting persons, dated August 14, 2025.
OptiNose, Inc. filing discloses that Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon and Gilad Aharon report beneficial ownership of 0 common shares (0.0%) of OptiNose common stock. The filing lists no sole or shared voting power and no sole or shared dispositive power for any reporting person.
The statement identifies Rosalind Advisors as an adviser and Salamon and Aharon as portfolio managers and includes a certification that the securities are held in the ordinary course of business and were not acquired to influence control; ownership is reported as 5% or less.
FAQ
What is the current stock price of Optinose (OPTN)?
What is the market cap of Optinose (OPTN)?
